Targetable ERBB2 mutations independently predict an aggressive phenotype in primary, ERBB2 non-amplified, hormone receptor positive lobular breast cancer

被引：0
|
作者：
Kurozumi, Sasagu [1 ]
Green, Andrew R. [1 ]
Ellis, Ian O. [1 ]
Rakha, Emad A. [1 ]
Fujii, Takaaki [2 ]
Shirabe, Ken [2 ]
Heery, David [3 ]
Zwart, Wilbert [4 ]
Oesterreich, Steffi [5 ,6 ]
Johnston, Simon J. [1 ]
机构：
[1] Univ Nottingham, Nottingham Breast Canc Res Ctr, Nottingham, England
[2] Gunma Univ, Dept Gen Surg Sci, Grad Sch Med, Gunma, Japan
[3] Univ Nottingham, Sch Pharm, Gene Regulat Lab, Nottingham, England
[4] Netherlands Canc Inst, Amsterdam, Netherlands
[5] UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA USA
[6] Magee Women Res Inst, Pittsburgh, PA USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P1-18-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-06
引用
收藏
页数：2
相关论文
共 50 条
  • [21] High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features
    Manuel Rosa-Rosa, Juan
    Caniego-Casas, Tamara
    Leskela, Susanna
    Cristobal, Eva
    Gonzalez-Martinez, Silvia
    Moreno-Moreno, Esther
    Lopez-Miranda, Elena
    Holgado, Esther
    Perez-Mies, Belen
    Garrido, Pilar
    Palacios, Jose
    CANCERS, 2019, 11 (01)
  • [22] DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
    Bi, Yanli
    Chen, Xiaoyu
    Wei, Bajin
    Wang, Linchen
    Gong, Longyuan
    Li, Haomin
    Xiong, Xiufang
    Zhao, Yongchao
    THERANOSTICS, 2021, 11 (13): : 6355 - 6369
  • [23] Genomic alterations in ERBB2 define a subset of pleomorphic invasive lobular breast cancer
    Hirshfield, Kim M.
    Sanders, Renee
    Feld, Heather K.
    Barnard, Nicola
    Liang, Li
    Zhong, Hua
    Bhanot, Gyan
    Sahota, Amrik S.
    Brooks, Andrew
    Rodriguez-Rodriguez, Lorna
    Ganesan, Shridar
    CANCER RESEARCH, 2015, 75
  • [24] Flotillins as regulators of ErbB2 levels in breast cancer
    Pust, S.
    Klokk, T. I.
    Musa, N.
    Jenstad, M.
    Risberg, B.
    Erikstein, B.
    Tcatchoff, L.
    Liestol, K.
    Danielsen, H. E.
    van Deurs, B.
    Sandvig, K.
    ONCOGENE, 2013, 32 (29) : 3443 - 3451
  • [25] Evaluation of agents targeting ErbB2 in breast cancer
    Kuruppu, A.
    Zhang, L.
    Thomas, N.
    Bradshaw, T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S209 - S209
  • [26] ERBB2 (HER2) Testing in Breast Cancer
    Hilal, Talal
    Romond, Edward H.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (12): : 1280 - 1281
  • [27] Treatment of ErbB2 breast cancer by mitochondrial targeting
    Sophia Eldad
    Rachel Hertz
    Gilad Vainer
    Ann Saada
    Jacob Bar-Tana
    Cancer & Metabolism, 8
  • [28] Treatment of ErbB2 breast cancer by mitochondrial targeting
    Eldad, Sophia
    Hertz, Rachel
    Vainer, Gilad
    Saada, Ann
    Bar-Tana, Jacob
    CANCER & METABOLISM, 2020, 8 (01)
  • [29] Flotillins as regulators of ErbB2 levels in breast cancer
    S Pust
    T I Klokk
    N Musa
    M Jenstad
    B Risberg
    B Erikstein
    L Tcatchoff
    K Liestøl
    H E Danielsen
    B van Deurs
    K Sandvig
    Oncogene, 2013, 32 : 3443 - 3451
  • [30] Dual targeting of ErbB1 and ErbB2 enhances response to chemotherapy in ErbB2 overexpressing breast cancer cell lines.
    O'Donovan, N.
    Clynes, M.
    Crown, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S105 - S105
12345